DDrare: Database of Drug Development for Rare Diseases

Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2011-2012 seasonal flu vaccine Intramuscular; 2011-2012 seasonal flu vaccine Subcutaneous; 4-Aminopyridine; 4-aminopyridine; 4-cholesten-3-one, oxime; 4-cholesten-3-one,oxime; AVXS-101; AVXS-101 (previously known as scAAV9.CB.SMN); Adipose derived mesenchymal stem cell; Air; Amifampridine; Amifampridine Phosphate; Amifampridine Phosphate 10 MG Oral Tablet; Biocarn; Branaplam; Celecoxib; GH; HUMAN ANTI-PROMYOSTATIN MONOCLONAL ANTIBODY; Hydroxyurea; ISIS 396443; ISIS 396443 (BIIB058); ISIS 396443, BIIB058; Itraconazole; LEVOCARNITINE; LMI070; Leuprolide; Levocarnitine; Mestinon; Midazolam; N.a.; NUSINERSEN; NUSINERSEN SODIUM; Nerve Growth Factor; Norditropin SimpleXx; Norditropin SimpleXx 15 mg/1.5 ml; Nursinersen; Nusinersen; Nusinersen Injectable Product; Nusinersen Treatments; OLESOXIME; ONASEMNOGENE ABEPARVOVEC; Olesoxime; Onasemnogene Abeparvovec-xioi; Onasemnogene abeparvovec; Onasemnogene abeparvovec-xioi; Orfiril Saft; Other: Monthly assessments of functional motor abilities by a trained therapist; Other: Prospective observational registry; PARACETAMOL; Paracetamol; Paracetamol 120Mg/5mL Oral Suspension; Phenylbutyrate; Phosphate; Placebo; Procedure: Air stacking manuever; Procedure: Sham Procedure; Procedure: Sham procedure; Pyridostigmine; Pyridostigmine Bromide; Pyridostigmine bromide; RO6885247; RO6885247/F02; RO6885247/F03; RO7034067; RO7034067 / F12; RO7034067 / F13; RO7034067/F06 + solvente (RO; RO7034067/F06 with solvent (RO7034067/F08); RO7034067/F07 + solvente (RO; RO7034067/F07 with solvent (RO7034067/F09); RO7034067/F12; RO7034067/F13; RO7090919; RVG 03820; Reldesemtiv; Reldesemtiv 150 mg; Reldesemtiv 450 mg; Riluzole; Risdiplam; SESAME OIL, REFINED; SMART; SRK-015; Salbutamol; Sesame oil; Sodium phenylbutyrate; Sodium phenylbutyrate (NaPB); Somatotropin; Somatropin; Spinraza; Survival of Motor Neuron 2 (SMN2) Splicing Modulator Antisense Oligonucleotide; TRO19622; Testosterone; VALPROATE SODIUM; VOLMAX*30CPR 4MG R.P.; VPA; Valproate; Valproate, Levocarnitine; Valproic Acid; Valproic Acid (VPA); Valproic Acid and Levocarnitine; Valproic acid; Zolgensma

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JMA-IIA00259	16/08/2016	10/08/2016	Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy : Continuous administration trial	Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy : Continuous administration trial	spinal muscular atrophy	Intervention type:DRUG. Intervention1:SMART, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:VPA 12.5mg/kg or 25mg/kg is to be taken once a day after supper..	Institute of Medical Genetics, Tokyo Women's Medical University	NULL	Recruiting	>=1 YEARS	<8 YEARS	BOTH	28	Phase 2B	Japan
2	JPRN-JMA-IIA00231	29/01/2016	01/12/2015	Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy : Confirmatory Trial	Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy : Confirmatory Trial	spinal muscular atrophy	Intervention type:DRUG. Intervention1:SMART, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:VPA 12.5mg/kg or 25mg/kg is to be taken once a day after supper.. Control intervention1:Placebo, Dose form:GRANULES, Route of administration:ORAL, Intended dose regimen:Placebo is to be taken once a day after supper..	Institute of Medical Genetics, Tokyo Women's Medical University	NULL	Completed	>=1 YEARS	<7 YEARS	BOTH	28	Phase 2B	Japan
3	JPRN-JMA-IIA00190	22/07/2014	01/08/2014	Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy	Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy	spinal muscular atrophy	Intervention type:DRUG. Intervention1:SMART, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:VPA is to be taken once a day after supper. Administration of VPA starts with an initial dosage (standard dose: 12.5 mg / kg) for 4 weeks. The dosage then increases to a maintenance dosage (standard dose: 25 mg/kg) from the 5th week to the 12th week. Administration, however, could be increased to an additional 50 mg/day in case of a blood concentration of VPA below 50 mcg/mL From the 13th week, administered doses are to be decreased (standard dose: 12.5 mg/kg) and continued to the 14th week. . Control intervention1:No.	Institute of Medical Genetics, Tokyo Women's Medical University	NULL	Completed	No Limit	<8 YEARS	BOTH	13	Phase 2A	Japan
4	NCT01671384 (ClinicalTrials.gov)	August 2013	13/8/2012	Valproate and Levocarnitine in Children With Spinal Muscular Atrophy	Randomized Placebo Controlled Trial of Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Aged 2-15 Years	Spinal Muscular Atrophy	Drug: Valproate , Levocarnitine;Drug: Placebo	All India Institute of Medical Sciences, New Delhi	NULL	Recruiting	2 Years	15 Years	Both	60	Phase 3	India
5	EUCTR2008-003915-11-DE (EUCTR)	24/09/2009	25/06/2009	Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I) - CARNI-VAL Type I	Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I) - CARNI-VAL Type I	Spinal Muscular Atrophy Type I in infants MedDRA version: 9.1;Level: LLT;Classification code 10051203;Term: Spinal muscular atrophy congenital	Trade Name: Orfiril Saft INN or Proposed INN: VALPROATE SODIUM Trade Name: Biocarn INN or Proposed INN: LEVOCARNITINE	University of Utah	NULL	Not Recruiting			Female: yes Male: yes	36	Phase 1;Phase 2	Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00661453 (ClinicalTrials.gov)	April 2008	14/4/2008	CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I	Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)	Spinal Muscular Atrophy Type I	Drug: Valproic Acid and Levocarnitine	University of Utah	Families of Spinal Muscular Atrophy;Leadiant Biosciences, Inc.	Completed	N/A	12 Months	All	40	Phase 1;Phase 2	United States;Canada;Germany
7	NCT00481013 (ClinicalTrials.gov)	July 2007	30/5/2007	Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy	Prospective Controlled Trial of Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy (VALIANTSMA) Study	Spinal Muscular Atrophy	Drug: Valproic Acid (VPA);Drug: Placebo	University of Utah	Families of Spinal Muscular Atrophy;Abbott	Completed	18 Years	60 Years	Both	33	Phase 2	United States
8	NCT00227266 (ClinicalTrials.gov)	September 2005	23/9/2005	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)	Spinal Muscular Atrophy	Drug: Valproic Acid and Levocarnitine;Drug: Placebo	University of Utah	Families of Spinal Muscular Atrophy;Leadiant Biosciences, Inc.;Abbott	Completed	2 Years	17 Years	All	94	Phase 2	United States;Canada
9	NCT00374075 (ClinicalTrials.gov)	September 2003	6/9/2006	Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy	In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy	Spinal Muscular Atrophy	Drug: Valproic Acid	University of Utah	Families of Spinal Muscular Atrophy;Sigma Tau Pharmaceuticals, Inc.;Abbott	Completed	2 Years	N/A	Both	42	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-JMA-IIA00259

16/08/2016

10/08/2016

Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy : Continuous administration trial

spinal muscular atrophy

Intervention type:DRUG. Intervention1:SMART, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:VPA 12.5mg/kg or 25mg/kg is to be taken once a day after supper..

Institute of Medical Genetics, Tokyo Women's Medical University

NULL

Recruiting

>=1 YEARS

<8 YEARS

BOTH

Phase 2B

Japan

JPRN-JMA-IIA00231

29/01/2016

01/12/2015

Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy : Confirmatory Trial

spinal muscular atrophy

Intervention type:DRUG. Intervention1:SMART, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:VPA 12.5mg/kg or 25mg/kg is to be taken once a day after supper.. Control intervention1:Placebo, Dose form:GRANULES, Route of administration:ORAL, Intended dose regimen:Placebo is to be taken once a day after supper..

Institute of Medical Genetics, Tokyo Women's Medical University

NULL

Completed

>=1 YEARS

<7 YEARS

BOTH

Phase 2B

Japan

JPRN-JMA-IIA00190

22/07/2014

01/08/2014

Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy

spinal muscular atrophy

Intervention type:DRUG. Intervention1:SMART, Dose form:GRANULES, Route of administration:ORAL, intended dose regimen:VPA is to be taken once a day after supper.
Administration of VPA starts with an initial dosage (standard dose: 12.5 mg / kg) for 4 weeks.
The dosage then increases to a maintenance dosage (standard dose: 25 mg/kg) from the 5th week to the 12th week. Administration, however, could be increased to an additional 50 mg/day in case of a blood concentration of VPA below 50 mcg/mL
From the 13th week, administered doses are to be decreased (standard dose: 12.5 mg/kg) and continued to the 14th week. . Control intervention1:No.

Institute of Medical Genetics, Tokyo Women's Medical University

NULL

Completed

No Limit

<8 YEARS

BOTH

Phase 2A

Japan

NCT01671384
(ClinicalTrials.gov)

August 2013

13/8/2012

Valproate and Levocarnitine in Children With Spinal Muscular Atrophy

Randomized Placebo Controlled Trial of Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Aged 2-15 Years

Spinal Muscular Atrophy

Drug: Valproate , Levocarnitine;Drug: Placebo

All India Institute of Medical Sciences, New Delhi

NULL

Recruiting

2 Years

15 Years

Both

Phase 3

India

EUCTR2008-003915-11-DE
(EUCTR)

24/09/2009

25/06/2009

Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I) - CARNI-VAL Type I

Spinal Muscular Atrophy Type I in infants
MedDRA version: 9.1;Level: LLT;Classification code 10051203;Term: Spinal muscular atrophy congenital

Trade Name: Orfiril Saft
INN or Proposed INN: VALPROATE SODIUM
Trade Name: Biocarn
INN or Proposed INN: LEVOCARNITINE

University of Utah

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00661453
(ClinicalTrials.gov)

April 2008

14/4/2008

CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I

Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)

Spinal Muscular Atrophy Type I

Drug: Valproic Acid and Levocarnitine

University of Utah

Families of Spinal Muscular Atrophy;Leadiant Biosciences, Inc.

Completed

N/A

12 Months

All

Phase 1;Phase 2

United States;Canada;Germany

NCT00481013
(ClinicalTrials.gov)

July 2007

30/5/2007

Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy

Prospective Controlled Trial of Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy (VALIANTSMA) Study

Spinal Muscular Atrophy

Drug: Valproic Acid (VPA);Drug: Placebo

University of Utah

Families of Spinal Muscular Atrophy;Abbott

Completed

18 Years

60 Years

Both

Phase 2

United States

NCT00227266
(ClinicalTrials.gov)

September 2005

23/9/2005

Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy

Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)

Spinal Muscular Atrophy

Drug: Valproic Acid and Levocarnitine;Drug: Placebo

University of Utah

Families of Spinal Muscular Atrophy;Leadiant Biosciences, Inc.;Abbott

Completed

2 Years

17 Years

All

Phase 2

United States;Canada

NCT00374075
(ClinicalTrials.gov)

September 2003

6/9/2006

Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy

In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy

Spinal Muscular Atrophy

Drug: Valproic Acid

University of Utah

Families of Spinal Muscular Atrophy;Sigma Tau Pharmaceuticals, Inc.;Abbott

Completed

2 Years

N/A

Both

Phase 1

United States